COAG
Hemab Therapeutics Holdings, Inc.$49.39
After hrs
$49.49
+0.20%
Mkt Cap $99.2M
52w Low $23.00
90.5% of range
52w High $52.15
50d MA $30.02
200d MA $29.91
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
—
ROE
—
P/FCF
—
RSI (14)
74.20
ATR (14)
$4.09
Beta
—
50d MA
$30.02
200d MA
$29.91
Avg Volume
—
CIK (SEC)
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 | AMC | -23.25 | -23.98 | -3.2% | 26.30 | +0.0% | -1.6% | +7.5% | +2.7% | -2.1% | +1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 | H.C. Wainwright | Initiates | Buy | $40 | $25.51 | $26.21 | +2.7% | +3.7% | +10.5% | +8.5% | -8.2% | -1.4% |
| May 26 | Evercore ISI | Initiates | Outperform | $50 | $25.89 | $26.75 | +3.3% | +7.5% | +2.7% | -2.1% | +1.8% | -4.8% |
| May 26 | Goldman | Initiates | Buy | $36 | $25.89 | $26.75 | +3.3% | +7.5% | +2.7% | -2.1% | +1.8% | -4.8% |
| May 26 | Jefferies | Initiates | Buy | $39 | $25.89 | $26.75 | +3.3% | +7.5% | +2.7% | -2.1% | +1.8% | -4.8% |
| May 26 | Wedbush | Initiates | Outperform | $42 | $25.89 | $26.75 | +3.3% | +7.5% | +2.7% | -2.1% | +1.8% | -4.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 61,523 | $24.98 | $1.5M | 6,444,637 | +10.55% | -3.62% |
| Jun 15, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 6,146 | $24.89 | $153K | 6,383,114 | +10.55% | -3.62% |
| May 20, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 996 | $24.94 | $25K | 6,376,968 | -1.56% | +1.79% |
| May 19, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 3,802 | $24.97 | $95K | 6,375,972 | -1.56% | +1.79% |
| May 12, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 6,387 | $24.90 | $159K | 6,372,170 | -1.06% | -0.64% |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 25,720 | $25.00 | $643K | 6,365,783 | +3.60% | -3.28% |
| May 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 14,149 | $24.47 | $346K | 6,340,063 | +3.60% | -3.28% |
| May 8, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 1,483 | $24.98 | $37K | 6,325,914 | +3.60% | -3.28% |
| May 7, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 1,985 | $24.95 | $50K | 6,324,431 | +3.60% | -3.28% |
| May 7, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 7,921 | $24.34 | $193K | 6,322,446 | +3.60% | -3.28% |
| May 6, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 53,407 | $24.83 | $1.3M | 6,314,525 | +2.92% | +10.27% |
| May 6, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 14,611 | $23.77 | $347K | 6,261,118 | +2.92% | +10.27% |
| May 5, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 10,268 | $25.00 | $257K | 6,246,507 | +2.92% | +10.27% |
| May 5, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 87,143 | $24.59 | $2.1M | 6,236,239 | +2.92% | +10.27% |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 133,750 | $18.00 | $2.4M | 354,938 | +2.92% | +10.27% |
| May 4, 2026 | RA CAPITAL MANAGEMENT, L.P. | — | Buy | 2,541,250 | $18.00 | $45.7M | 6,149,096 | +2.92% | +10.27% |
8-K
Hemab Therapeutics Holdings, Inc. -- 8-K Filing
Hemab Therapeutics' sutacimig received FDA Breakthrough Therapy Designation for Glanzmann thrombasthenia, potentially accelerating development and approval timelines for this rare blood disorder treatment.
May 21
8-K
Hemab Therapeutics Holdings, Inc. -- 8-K Filing
Hemab Therapeutics (COAG) completed its IPO on May 4, 2026, with amended bylaws and restated certificate of incorporation taking effect at closing.
May 4
Valuation
Market Cap
$99.2M
Enterprise Value
—
P/E (TTM)
—
Forward P/E
—
PEG Ratio
—
P/B
—
P/S
—
P/FCF
—
EV/EBITDA
—
Shares Out
—
Financials (TTM)
Revenue
—
Net Income
—
EBITDA
—
Free Cash Flow
—
Op Cash Flow
—
EPS Basic
—
EPS Diluted
—
EPS Forward
—
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
—
Total Liab.
—
Total Equity
—
Cash
—
LT Debt
—
Book Value/Sh
—
Debt/Equity
—
Current Ratio
—
Quick Ratio
—
Returns & Growth
ROE
—
ROA
—
ROIC
—
Rev Growth YoY
—
EPS Growth YoY
—
Price Returns
2W
+59.0%
1M
+68.6%
3M
+45.0%
6M
+45.0%
12M
+45.0%
Technicals
52W High
$52.15
52W Low
$23.00
50d MA
$30.02
200d MA
$29.91
RSI (14)
74.20
ATR (14)
$4.09
Beta
—
Avg Volume
—
Dividends
Div Rate
—
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
· Source: financialmodelingprep.com